Veritas In Silico (TSE:130A) Total Operating Expense: 円264.50 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:130A Veritas In Silico Inc TSE:130A
11 GF Score
Price 円418.00
! 4 Warning Signs
View Full Analysis

What is Veritas In Silico Total Operating Expense?

Veritas In Silico TSE:130A -3.91% 11 Total Operating Expense is 円264.50 Mil as of Dec. 2025. GuruFocus rates TSE:130A with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

Veritas In Silico's Total Operating Expense for the three months ended in Dec. 2025 was 円0.00 Mil. Veritas In Silico's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was 円264.50 Mil.

Veritas In Silico Total Operating Expense Related Terms

Veritas In Silico Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Veritas In Silico's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veritas In Silico Total Operating Expense Chart

Veritas In Silico Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
294.84 317.71 322.73 407.49 487.89

Veritas In Silico Quarterly Data
Dec21 Dec22 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 105.18 124.50 0.00 0.00 140.00
TSE:130A
11GF Score
Veritas In Silico Inc TSE:130A
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veritas In Silico Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円264.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of 円264.50 Mil mean?
Veritas In Silico (TSE:130A) has a Total Operating Expense of 円264.50 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Veritas In Silico and its competitors.
Is Veritas In Silico's Total Operating Expense too high?
Veritas In Silico's current Total Operating Expense is 円264.50 Mil. Overall, Veritas In Silico has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Veritas In Silico's Total Operating Expense compare to VRTX and REGN?
Veritas In Silico's Total Operating Expense of 円264.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Veritas In Silico and its competitors. Veritas In Silico's current Total Operating Expense is 円264.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veritas In Silico stock overvalued right now?
Veritas In Silico (TSE:130A) has a current Total Operating Expense of 円264.50 Mil. The current Total Operating Expense is 円264.50 Mil. Veritas In Silico's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Veritas In Silico (TSE:130A), the current Total Operating Expense is 円264.50 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veritas In Silico Business Description

Address 1-11-1, Nishigotanda, Shinagawa-ku, Tokyo, JPN, 141-0031
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
11GF Score

Get the complete analysis for TSE:130A

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円418.00
Price